ResearcherHenan UniversityNo recent work listed

Dandan Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2578-7324; OpenAlex author ID A5101736245. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 6

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 3

Gut Streptococcus is a microbial marker for the occurrence and liver metastasis of pancreatic cancer. Co-author DOI 10.3389/fmicb.2023.1184869 ↗
SOX21-AS1 activated by STAT6 promotes pancreatic cancer progression via up-regulation of SOX21. Co-author DOI 10.1186/s12967-022-03521-5 ↗
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic ca… Co-author DOI 10.1186/s12885-021-08605-x ↗

Closest collaborators

The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Hongli Liu · 1 shared paper, 2023 · strength 0.18
- Paper Gut Streptococcus is a microbial marker for the occurrence and liver metastasis of pancreatic cancer. DOI 10.3389/fmicb.2023.1184869 ↗
Jinru Yang · 1 shared paper, 2023 · strength 0.18
- Paper Gut Streptococcus is a microbial marker for the occurrence and liver metastasis of pancreatic cancer. DOI 10.3389/fmicb.2023.1184869 ↗
Shishi Qiao · 1 shared paper, 2022 · strength 0.17
- Paper SOX21-AS1 activated by STAT6 promotes pancreatic cancer progression via up-regulation of SOX21. DOI 10.1186/s12967-022-03521-5 ↗
Guanghui Zhu · 1 shared paper, 2022 · strength 0.17
- Paper SOX21-AS1 activated by STAT6 promotes pancreatic cancer progression via up-regulation of SOX21. DOI 10.1186/s12967-022-03521-5 ↗
Zhenyu Lin · 1 shared paper, 2021 · strength 0.13
- Paper Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-lin… DOI 10.1186/s12885-021-08605-x ↗
Jiayuan Chen · 1 shared paper, 2021 · strength 0.13
- Paper Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-lin… DOI 10.1186/s12885-021-08605-x ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.